Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.

Sjödahl G, Eriksson P, Patschan O, Marzouka NA, Jakobsson L, Bernardo C, Lövgren K, Chebil G, Zwarthoff E, Liedberg F, Höglund M.

Int J Cancer. 2020 May 1;146(9):2636-2647. doi: 10.1002/ijc.32737. Epub 2019 Nov 14.

2.

Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival.

Kollberg P, Chebil G, Eriksson P, Sjödahl G, Liedberg F.

Urol Oncol. 2019 Oct;37(10):791-799. doi: 10.1016/j.urolonc.2019.04.010. Epub 2019 May 2.

PMID:
31056435
3.

Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays.

Jakobsson L, Chebil G, Marzouka NA, Liedberg F, Sjödahl G.

Bladder Cancer. 2018 Jul 30;4(3):327-337. doi: 10.3233/BLC-180176.

4.

HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.

Eriksson P, Sjödahl G, Chebil G, Liedberg F, Höglund M.

Oncotarget. 2017 Jul 25;8(30):48905-48914. doi: 10.18632/oncotarget.16554.

5.

St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.

Falck AK, Röme A, Fernö M, Olsson H, Chebil G, Bendahl PO, Rydén L.

Br J Surg. 2016 Apr;103(5):513-23. doi: 10.1002/bjs.10070. Epub 2016 Feb 9.

6.

A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.

Patschan O, Sjödahl G, Chebil G, Lövgren K, Lauss M, Gudjonsson S, Kollberg P, Eriksson P, Aine M, Månsson W, Fernö M, Liedberg F, Höglund M.

Eur Urol. 2015 Nov;68(5):824-32; discussion 835-6. doi: 10.1016/j.eururo.2015.02.021. Epub 2015 Mar 11.

PMID:
25770486
7.

Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.

Sjödahl G, Lövgren K, Lauss M, Chebil G, Patschan O, Gudjonsson S, Månsson W, Fernö M, Leandersson K, Lindgren D, Liedberg F, Höglund M.

Urol Oncol. 2014 Aug;32(6):791-7. doi: 10.1016/j.urolonc.2014.02.007. Epub 2014 Apr 29.

8.

Toward a molecular pathologic classification of urothelial carcinoma.

Sjödahl G, Lövgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, Aine M, Eriksson P, Månsson W, Lindgren D, Fernö M, Liedberg F, Höglund M.

Am J Pathol. 2013 Sep;183(3):681-91. doi: 10.1016/j.ajpath.2013.05.013. Epub 2013 Jul 1.

9.

Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

Falck AK, Bendahl PO, Chebil G, Olsson H, Fernö M, Rydén L.

Breast Cancer Res Treat. 2013 Jul;140(1):93-104. doi: 10.1007/s10549-013-2617-8. Epub 2013 Jun 27.

PMID:
23807420
10.

The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.

Strand C, Bak M, Borgquist S, Chebil G, Falck AK, Fjällskog ML, Grabau D, Hedenfalk I, Jirström K, Klintman M, Malmström P, Olsson H, Rydén L, Stål O, Bendahl PO, Fernö M.

Springerplus. 2013 Dec;2(1):111. doi: 10.1186/2193-1801-2-111. Epub 2013 Mar 14.

11.

Bladder wash cytology at diagnosis of Ta-T1 bladder cancer is predictive for recurrence and progression.

Jancke G, Rosell J, Chebil G, Jahnson S.

Urology. 2012 Sep;80(3):625-31. doi: 10.1016/j.urology.2012.04.049.

PMID:
22925239
12.

DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status.

Lauss M, Aine M, Sjödahl G, Veerla S, Patschan O, Gudjonsson S, Chebil G, Lövgren K, Fernö M, Månsson W, Liedberg F, Ringnér M, Lindgren D, Höglund M.

Epigenetics. 2012 Aug;7(8):858-67. doi: 10.4161/epi.20837. Epub 2012 Jun 18.

13.

The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading.

Liedberg F, Lauss M, Patschan O, Aine M, Chebil G, Cwikiel M, Engilbertsson H, Gudjonsson S, Kollberg P, Sjödahl G, Månsson W, Lindgren D, Höglund M; Lund Bladder Cancer Group.

Eur Urol. 2012 Oct;62(4):620-3. Epub 2012 Jun 5. No abstract available.

PMID:
22698575
14.

Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.

Lindgren D, Sjödahl G, Lauss M, Staaf J, Chebil G, Lövgren K, Gudjonsson S, Liedberg F, Patschan O, Månsson W, Fernö M, Höglund M.

PLoS One. 2012;7(6):e38863. doi: 10.1371/journal.pone.0038863. Epub 2012 Jun 7.

15.

A molecular taxonomy for urothelial carcinoma.

Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, Månsson W, Liedberg F, Lindgren D, Höglund M.

Clin Cancer Res. 2012 Jun 15;18(12):3377-86. doi: 10.1158/1078-0432.CCR-12-0077-T. Epub 2012 May 2.

16.

The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS).

Gudjónsson S, Bläckberg M, Chebil G, Jahnson S, Olsson H, Bendahl PO, Månsson W, Liedberg F.

BJU Int. 2012 Jul;110(2 Pt 2):E41-5. doi: 10.1111/j.1464-410X.2011.10654.x. Epub 2011 Oct 28.

17.

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

Sjödahl G, Lauss M, Gudjonsson S, Liedberg F, Halldén C, Chebil G, Månsson W, Höglund M, Lindgren D.

PLoS One. 2011 Apr 14;6(4):e18583. doi: 10.1371/journal.pone.0018583.

18.

Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer?

Gudjónsson S, Bendahl PO, Chebil G, Höglund M, Lindgren D, Lundberg LM, Lövgren K, Fernö M, Månsson W, Liedberg F.

Scand J Urol Nephrol. 2011 Sep;45(4):270-7. doi: 10.3109/00365599.2011.568956. Epub 2011 Apr 20.

PMID:
21504385
19.

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

Lindgren D, Frigyesi A, Gudjonsson S, Sjödahl G, Hallden C, Chebil G, Veerla S, Ryden T, Månsson W, Liedberg F, Höglund M.

Cancer Res. 2010 May 1;70(9):3463-72. doi: 10.1158/0008-5472.CAN-09-4213. Epub 2010 Apr 20.

20.

MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31.

Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, Månsson W, Rovira C, Höglund M.

Int J Cancer. 2009 May 1;124(9):2236-42. doi: 10.1002/ijc.24183.

21.

Recurrent and multiple bladder tumors show conserved expression profiles.

Lindgren D, Gudjonsson S, Jee KJ, Liedberg F, Aits S, Andersson A, Chebil G, Borg A, Knuutila S, Fioretos T, Månsson W, Höglund M.

BMC Cancer. 2008 Jun 30;8:183. doi: 10.1186/1471-2407-8-183.

22.

Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors.

Heidenblad M, Lindgren D, Jonson T, Liedberg F, Veerla S, Chebil G, Gudjonsson S, Borg A, Månsson W, Höglund M.

BMC Med Genomics. 2008 Jan 31;1:3. doi: 10.1186/1755-8794-1-3.

23.

Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail?

Liedberg F, Anderson H, Chebil G, Gudjonsson S, Höglund M, Lindgren D, Lundberg LM, Lövgren K, Fernö M, Månsson W.

Urol Oncol. 2008 Jan-Feb;26(1):17-24. doi: 10.1016/j.urolonc.2006.08.021. Epub 2007 Oct 22.

PMID:
18190825
24.

Prospective study of transitional cell carcinoma in the prostatic urethra and prostate in the cystoprostatectomy specimen. Incidence, characteristics and preoperative detection.

Liedberg F, Anderson H, Bläckberg M, Chebil G, Davidsson T, Gudjonsson S, Jahnson S, Olsson H, Månsson W.

Scand J Urol Nephrol. 2007;41(4):290-6.

PMID:
17763219
25.

Distinct mitotic segregation errors mediate chromosomal instability in aggressive urothelial cancers.

Jin Y, Stewénius Y, Lindgren D, Frigyesi A, Calcagnile O, Jonson T, Edqvist A, Larsson N, Lundberg LM, Chebil G, Liedberg F, Gudjonsson S, Månsson W, Höglund M, Gisselsson D.

Clin Cancer Res. 2007 Mar 15;13(6):1703-12.

26.

Urothelial carcinoma in the prostatic urethra and prostate: current controversies.

Liedberg F, Chebil G, Månsson W.

Expert Rev Anticancer Ther. 2007 Mar;7(3):383-90. Review.

PMID:
17338657
28.

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.

Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, Månsson W, Fioretos T, Höglund M.

Oncogene. 2006 Apr 27;25(18):2685-96.

PMID:
16532037
29.

Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer.

Liedberg F, Chebil G, Davidsson T, Gudjonsson S, Månsson W.

J Urol. 2006 Jan;175(1):84-8; discussion 88-9.

PMID:
16406877
30.

Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.

Jirström K, Rydén L, Anagnostaki L, Nordenskjöld B, Stål O, Thorstenson S, Chebil G, Jönsson PE, Fernö M, Landberg G.

J Clin Pathol. 2005 Nov;58(11):1135-42.

31.

[HER2 testing for breast cancer. Swedish laboratories can now offer a quality assured analysis of growth factor].

Haglund M, Chebil G, Johansson L.

Lakartidningen. 2005 Mar 7-13;102(10):740-3. Swedish.

PMID:
15839164
32.

Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.

Rydén L, Jönsson PE, Chebil G, Dufmats M, Fernö M, Jirström K, Källström AC, Landberg G, Stål O, Thorstenson S, Nordenskjöld B; South Swedish Breast Cancer Group; South-East Swedish Breast Cancer Group.

Eur J Cancer. 2005 Jan;41(2):256-64.

PMID:
15661551
33.

Predicting continuous values of prognostic markers in breast cancer from microarray gene expression profiles.

Gruvberger-Saal SK, Edén P, Ringnér M, Baldetorp B, Chebil G, Borg A, Fernö M, Peterson C, Meltzer PS.

Mol Cancer Ther. 2004 Feb;3(2):161-8.

35.

[Bladder cancer and the sentinel node concept].

Liedberg F, Chebil G, Davidsson T, Malmström PU, Sherif A, Thörn M, De La Torre M, Månsson W.

Aktuelle Urol. 2003 Mar;34(2):115-8. German.

PMID:
14566695
36.

[Transitional cell carcinoma of the prostate in cystoprostatectomy specimens].

Liedberg F, Chebil G, Davidsson T, Malmström PU, Sherif A, Månsson W.

Aktuelle Urol. 2003 Sep;34(5):333-6. German.

PMID:
14566661
37.

Hematogenous dissemination of transitional cell carcinoma in the bladder to the prostate.

Liedberg F, Chebil G, Månsson W.

Scand J Urol Nephrol. 2003;37(4):359-60.

PMID:
12944198
38.

Small bowel obstruction caused by intestinal metastases from undiagnosed breast cancer: report of two cases.

Rydén L, Chebil G, Jönsson PE.

Eur J Surg. 2002;168(11):648-50. No abstract available.

PMID:
12699105
39.

The nested variant of urothelial carcinoma: a rare but important bladder neoplasm with aggressive behavior. Three case reports and a review of the literature.

Liedberg F, Chebil G, Davidsson T, Gadaleanu V, Grabe M, Mansson W.

Urol Oncol. 2003 Jan-Feb;21(1):7-9. Review.

PMID:
12684120
40.

Estrogen and progesterone receptor assay in paraffin-embedded breast cancer--reproducibility of assessment.

Chebil G, Bendahl PO, Fernö M; South Sweden Breast Cancer Group; North Sweden Breast Cancer Group.

Acta Oncol. 2003;42(1):43-7.

PMID:
12665330
41.

Molecular classification of familial non-BRCA1/BRCA2 breast cancer.

Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G, Ach R, Loman N, Olsson H, Meltzer P, Borg A, Trent J.

Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2532-7. Epub 2003 Feb 27.

Supplemental Content

Loading ...
Support Center